Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.870 -0.030 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
News headline image
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness ↗
Photo by Raimond Klavins 
Via Benzinga
News headline image
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline ↗
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same... 
Via Talk Markets
Topics Cannabis
News headline image
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study ↗
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
News headline image
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000 ↗
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics... 
Via Benzinga
Topics Death
News headline image
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness ↗
Photo by Michael Longmire on... 
Via Benzinga
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways
Via Investor Brand Network
News headline image
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry ↗
Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent invest... 
Via Benzinga
News headline image
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November ↗
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance. 
Via Talk Markets
Topics Cannabis
News headline image
Analyst Ratings For ATAI Life Sciences ↗
Over the past 3 months, 6 analysts have published their opinion on ATAI Life Sciences (NASDAQ: 
Via Benzinga
News headline image
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways ↗
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021 ↗
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ: 
Via Benzinga
News headline image
Psychedelic Drug Stocks Continued To Decline Last Week ↗
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
News headline image
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November ↗
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
Via FinancialNewsMedia
News headline image
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others ↗
Compass Pathways reported 
Via Talk Markets
News headline image
Analyst Ratings For ATAI Life Sciences ↗
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT... 
Via Benzinga
News headline image
70 Biggest Movers From Yesterday ↗
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021 ↗
Upgrades Barrington Research upgraded the previous rating for Clear Channel Outdoor Holdings Inc (NYSE: 
Via Benzinga
News headline image
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial ↗
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon
Via Investor Brand Network
News headline image
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop ↗
Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug... 
Via Benzinga
Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”,... 
Via FinancialNewsMedia
Topics Law Enforcement
News headline image
ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study ↗
ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated... 
Via Benzinga
News headline image
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148% ↗
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD. 
Via Talk Markets
Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More
Via Investor Brand Network
News headline image
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
News headline image
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets. 
Via Talk Markets
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
News headline image
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗
The Week In Psychedelics 
Via Benzinga
News headline image
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.